Strategies to guide the antibody affinity maturation process

Current Opinion in Virology

Volumn 11, Issue , 2015, Pages 137-147

  Doria Rose, Nicole A ^a   Joyce, M Gordon ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CROSS REACTING ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE;

ANTIBODY AFFINITY; ANTIVIRAL ACTIVITY; ARTICLE; B LYMPHOCYTE; GERMINAL CENTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; INFLUENZA VIRUS; MATURATION; MICROBIAL DIVERSITY; NONHUMAN; PRIORITY JOURNAL; SOMATIC HYPERMUTATION; VIRUS ENVELOPE; VIRUS IMMUNITY; VIRUS NEUTRALIZATION; DRUG DEVELOPMENT; IMMUNOLOGY; ISOLATION AND PURIFICATION; ORTHOMYXOVIRIDAE; PROCEDURES; VACCINATION;

ANTIBODIES, VIRAL; ANTIBODY AFFINITY; DRUG DISCOVERY; HIV-1; HUMANS; ORTHOMYXOVIRIDAE; VACCINATION; VIRAL VACCINES;

EID: 84928948416     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2015.04.002     Document Type: Review

References (115)

1. I.C. MacLennan Germinal centers Annu Rev Immunol 12 1994 117 139
2. T.D. Chan, and R. Brink Affinity-based selection and the germinal center response Immunol Rev 247 2012 11 23
3. A.T. McGuire Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D J Virol 88 2014 2645 2657
4. A.T. McGuire HIV antibodies, antigen modification regulates competition of broad and narrow neutralizing HIV antibodies Science 346 2014 1380 1383
5. M. Bonsignori Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors J Virol 85 2011 9998 10009
6. N.A. Doria-Rose Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies Nature 509 2014 55 62
7. H.X. Liao Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus Nature 496 2013 469 476
8. J.F. Scheid Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding Science 333 2011 1633 1637
9. L.M. Walker Broad neutralization coverage of HIV by multiple highly potent antibodies Nature 477 2011 466 470
10. H. Mouquet Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies Proc Natl Acad Sci U S A 109 2012 E3268 E3277
11. D. Sok Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex Proc Natl Acad Sci U S A 111 2014 17624 17629
12. F. Klein Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants J Exp Med 211 2014 2361 2372
13. X. Wu Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1 Science 329 2010 856 861
14. M. Bonsignori Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design J Virol 86 2012 4688 4692
15. J.F. Scheid Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals Nature 458 2009 636 640
16. L.M. Walker Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target Science 326 2009 285 289
17. J. Wrammert Rapid cloning of high-affinity human monoclonal antibodies against influenza virus Nature 453 2008 667 671
18. L. Pappas Rapid development of broadly influenza neutralizing antibodies through redundant mutations Nature 516 2014 418 422
19. T. Zhou Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01 Science 329 2010 811 817
20. I.S. Georgiev Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline J Immunol 192 2014 1100 1106
21. A.P. West Jr. Structural basis for germline usage of a potent class of HIV-1 antibodies targeting the CD4 binding site Proc Natl Acad Sci U S A 109 2012 E2083 E2090
22. X. Wu Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing Science 333 2011 1593 1602
23. D. Lingwood Structural and genetic basis for development of broadly neutralizing influenza antibodies Nature 489 2012 566 570
24. J.R. Whittle Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stem-directed antibodies from multiple Ig heavy-chain lineages J Virol 88 2014 4047 4057
25. J.S. McLellan Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 Nature 480 2011 336 343
26. M. Pancera Structure and immune recognition of trimeric pre-fusion HIV-1 Env Nature 514 2014 455 461
27. R. Pejchal A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield Science 334 2011 1097 1103
28. J.R. Whittle Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin Proc Natl Acad Sci U S A 108 2011 14216 14221
29. D.C. Ekiert Cross-neutralization of influenza A viruses mediated by a single antibody loop Nature 489 2012 526 532
30. R. Xu A recurring motif for antibody recognition of the receptor-binding site of influenza hemagglutinin Nat Struct Mol Biol 20 2013 363 370
31. P.S. Lee Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity Proc Natl Acad Sci U S A 109 2012 17040 17045
32. G. Ofek Structural basis for HIV-1 neutralization by 2F5-like antibodies m66 and m66.6 J Virol 88 2014 2426 2441
33. J. Huang Broad and potent neutralization of HIV-1 by a gp41-specific human antibody Nature 491 2012 406 412
34. G. Ofek Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope J Virol 78 2004 10724 10737
35. R.M. Cardoso Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41 Immunity 22 2005 163 173
36. L. Morris Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting PLoS ONE 6 2011 pe23532
37. T. Zhou Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies Immunity 39 2013 245 258
38. K.J. Doores Two classes of broadly neutralizing antibodies within a single lineage directed to the high-mannose patch of HIV envelope J Virol 89 2015 1105 1118
39. D. Fera Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains Proc Natl Acad Sci U S A 111 2014 10275 10280
40. F. Gao Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies Cell 158 2014 481 491
41. P.L. Moore Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape Nat Med 18 2012 1688 1692
42. M.K. Murphy Viral escape from neutralizing antibodies in early subtype A HIV-1 infection drives an increase in autologous neutralization breadth PLoS Pathog 9 2013 pe1003173
43. C.K. Wibmer Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes PLoS Pathog 9 2013 pe1003738
44. M. Guttman Antibody potency relates to the ability to recognize the closed, pre-fusion form of HIV Env Nat Commun 6 2015 6144
45. M.G. Joyce Outer domain of HIV-1 gp120: antigenic optimization, structural malleability, and crystal structure with antibody VRC-PG04 J Virol 87 2013 2294 2306
46. J.S. McLellan Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus Science 342 2013 592 598
47. T. Tong HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes J Virol 86 2012 3574 3587
48. J.R. Mascola, and B.F. Haynes HIV-1 neutralizing antibodies: understanding nature's pathways Immunol Rev 254 2013 225 244
49. G.J. Tobin Deceptive imprinting and immune refocusing in vaccine design Vaccine 26 2008 6189 6199
50. I.K. Srivastava Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region J Virol 77 2003 2310 2320
51. S.A. Jeffs Truncated gp120 envelope glycoprotein of human immunodeficiency virus 1 elicits a broadly reactive neutralizing immune response J Gen Virol 83 Pt 11 2002 2723 2732
52. E.T. Crooks A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120 Virology 366 2007 245 262
53. J.R. Mascola, and D.C. Montefiori The role of antibodies in HIV vaccines Annu Rev Immunol 28 2010 413 444
54. X. Yang Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin J Virol 76 2002 4634 4642
55. K. Sliepen Immunosilencing a highly immunogenic protein trimerization domain J Biol Chem 290 2015 7436 7442
56. P. Pitisuttithum HIV-1 prophylactic vaccine trials in Thailand Curr HIV Res 3 2005 17 30
57. P. Pugach A native-like SOSIP.664 trimer based on a HIV-1 subtype B env gene J Virol 89 2015 3380 3395
58. R.W. Sanders A next-generation cleaved, soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies PLoS Pathog 9 2013 e1003618
59. R.P. Ringe Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation Proc Natl Acad Sci U S A 110 2013 18256 18261
60. C. Blattner Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers Immunity 40 2014 669 680
61. J. Huang Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface Nature 515 2014 138 142
62. D. Lyumkis Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer Science 342 2013 1484 1490
63. J.P. Julien Crystal structure of a soluble cleaved HIV-1 envelope trimer Science 342 2013 1477 1483
64. J. Jardine Rational HIV immunogen design to target specific germline B cell receptors Science 340 2013 711 716
65. A.T. McGuire Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies J Exp Med 210 2013 655 663
66. J.A. Horwitz HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice Proc Natl Acad Sci U S A 110 2013 16538 16543
67. R.M. Lynch HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies J Virol 89 2015 4201 4213
68. X. Wu Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site J Virol 86 2012 5844 5856
69. N. Pica, and P. Palese Toward a universal influenza virus vaccine: prospects and challenges Annu Rev Med 64 2013 189 202
70. A.J. Caton The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype) Cell 31 2 Pt 1 1982 417 427
71. I.A. Wilson, and N.J. Cox Structural basis of immune recognition of influenza virus hemagglutinin Annu Rev Immunol 8 1990 737 771
72. J.M. Fonville Antibody landscapes after influenza virus infection or vaccination Science 346 2014 996 1000
73. B.F. Koel Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution Science 342 2013 976 979
74. V.V. Mallajosyula Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection Proc Natl Acad Sci U S A 111 2014 E2514 E2523
75. F. Krammer, and P. Palese Influenza virus hemagglutinin stalk-based antibodies and vaccines Curr Opin Virol 3 2013 521 530
76. F. Krammer Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies J Virol 87 2013 6542 6550
77. C.A. Derdeyn, P.L. Moore, and L. Morris Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection Curr Opin HIV AIDS 9 2014 210 216
78. B.F. Haynes B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study Nat Biotechnol 30 2012 423 433
79. D.C. Malherbe Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits J Virol 88 2014 12949 12967
80. D.C. Malherbe Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies J Virol 85 2011 5262 5274
81. F. Pissani Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially Vaccine 30 2012 5519 5526
82. D. Corti Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine J Clin Invest 120 2010 1663 1673
83. G.M. Li Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells Proc Natl Acad Sci U S A 109 2012 9047 9052
84. J.H. Kim, J.L. Excler, and N.L. Michael Lessons from the RV144 Thai Phase III HIV-1 vaccine trial and the search for correlates of protection Annu Rev Med 66 2015 423 437
85. S. Zolla-Pazner Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection PLoS ONE 9 2014 pe87572
86. B.F. Haynes Immune-correlates analysis of an HIV-1 vaccine efficacy trial N Engl J Med 366 2012 1275 1286
87. G.G. Fouda Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses J Infect Dis 211 2015 508 517
88. S. Wang, B. Mata-Fink, and Kreigsman Manipulating the selection forces during affinity maturation to generate cross-reactive HIV antibodies Cell 2015 785 797
89. R.B. Belshe Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant J Infect Dis 203 2011 666 673
90. N.A. Doria-Rose Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables J Virol 84 2010 1631 1636
91. A. Piantadosi Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression J Virol 83 2009 10269 10274
92. D.N. Sather Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection J Virol 83 2009 757 769
93. S. Kwa CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge J Virol 88 2014 9579 9589
94. L.A. Lee, and Q. Wang Adaptations of nanoscale viruses and other protein cages for medical applications Nanomedicine 2 2006 137 149
95. M. Kanekiyo Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies Nature 499 2013 102 106
96. S.D. Xiang Pathogen recognition and development of particulate vaccines: does size matter? Methods 40 2006 1 9
97. V.V. Temchura Targeting and activation of antigen-specific B-cells by calcium phosphate nanoparticles loaded with protein antigen Biomaterials 35 2014 6098 6105
98. M.F. Bachmann The influence of antigen organization on B cell responsiveness Science 262 1993 1448 1451
99. Z. Yin Boosting immunity to small tumor-associated carbohydrates with bacteriophage qbeta capsids ACS Chem Biol 8 2013 1253 1262
100. B.N. Lambrecht Mechanism of action of clinically approved adjuvants Curr Opin Immunol 21 2009 23 29
101. S.G. Reed, M.T. Orr, and C.B. Fox Key roles of adjuvants in modern vaccines Nat Med 19 2013 1597 1608
102. J. Mattsson Complement activation and complement receptors on follicular dendritic cells are critical for the function of a targeted adjuvant J Immunol 187 2011 3641 3652
103. M. Bemark A unique role of the cholera toxin A1-DD adjuvant for long-term plasma and memory B cell development J Immunol 186 2011 1399 1410
104. M. Melchers Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses J Virol 86 2012 2488 2500
105. G.D. Victora Germinal center dynamics revealed by multiphoton microscopy with a photoactivatable fluorescent reporter Cell 143 2010 592 605
106. A.D. Gitlin, Z. Shulman, and M.C. Nussenzweig Clonal selection in the germinal centre by regulated proliferation and hypermutation Nature 509 2014 637 640
107. R.R. Kulkarni Activation of the RIG-I pathway during influenza vaccination enhances the germinal center reaction, promotes T follicular helper cell induction, and provides a dose-sparing effect and protective immunity J Virol 88 2014 13990 14001
108. J. Wrammert Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection J Exp Med 208 2011 181 193
109. L. He Toward a more accurate view of human B-cell repertoire by next-generation sequencing, unbiased repertoire capture and single-molecule barcoding Sci Rep 4 2014 6778
110. C. Sundling Single-cell and deep sequencing of IgG-switched macaque B cells reveal a diverse Ig repertoire following immunization J Immunol 192 2014 3637 3644
111. M. Apel, and C. Berek Somatic mutations in antibodies expressed by germinal centre B cells early after primary immunization Int Immunol 2 1990 813 819
112. J. Jacob Intraclonal generation of antibody mutants in germinal centres Nature 354 1991 389 392
113. M. Oprea, and A.S. Perelson Somatic mutation leads to efficient affinity maturation when centrocytes recycle back to centroblasts J Immunol 158 1997 5155 5162
114. J.S. McLellan Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes J Virol 85 2011 7788 7796
115. S.J. Gamblin The structure and receptor binding properties of the 1918 influenza hemagglutinin Science 303 2004 1838 1842